{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T02:07:46Z","timestamp":1785550066807,"version":"3.56.0"},"reference-count":0,"publisher":"Portico","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.1358\/dot.2021.57.11.3343691","type":"journal-article","created":{"date-parts":[[2021,11,18]],"date-time":"2021-11-18T07:58:28Z","timestamp":1637222308000},"page":"677","source":"Crossref","is-referenced-by-count":14,"title":["Naxitamab: a humanized anti-glycolipid disialoganglioside\n(anti-GD2) monoclonal antibody for treatment of neuroblastoma"],"prefix":"10.3730","volume":"57","author":[{"family":"Slatnick, L.R.","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Jimeno, A.","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Gore, L.","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Macy, M.E.","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1320","published-online":{"date-parts":[[2021]]},"container-title":["Drugs of Today"],"original-title":[],"deposited":{"date-parts":[[2023,5,30]],"date-time":"2023-05-30T13:32:25Z","timestamp":1685453545000},"score":1,"resource":{"primary":{"URL":"http:\/\/access.portico.org\/stable?au=pjbf7dct736"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021]]},"references-count":0,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1358\/dot.2021.57.11.3343691","relation":{},"ISSN":["1699-4019"],"issn-type":[{"value":"1699-4019","type":"print"}],"subject":[],"published":{"date-parts":[[2021]]}}}